Poliklinika SLAVONIJA OSIJEK za opcu kirurgiju radiologiju baromedicinu ginekologiju i porodiljstvo i internu medicinu
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Poliklinika Slavonija Osijek team is advancing research aimed at reducing the risk of major adverse cardiovascular events in high‑risk patients, while also exploring new options for hypertension and atherosclerotic disease prevention.
- Primary prevention of ASCVD
- Hypertension management strategies
- Combination therapy for heart failure outcomes
With five active studies and three dedicated investigators, the site contributes valuable data to cardiovascular care across Europe.
Hormonal diseases
Research at this clinic focuses on innovative treatments for type 2 diabetes, evaluating how new agents improve glycemic control and interact with existing therapies such as SGLT2 inhibitors.
- Glucose‑lowering drug efficacy
- Combination regimens with empagliflozin
- Impact on insulin resistance and metabolic markers
The investigations support the hospital’s commitment to advancing endocrine health for patients in Croatia and beyond.
Nutritional and Metabolic Diseases
The centre is conducting trials that target overweight and obesity, testing novel peptides and lifestyle‑enhanced interventions to achieve meaningful weight loss in adults with metabolic risk factors.
- Weekly peptide therapies for weight reduction
- Adjunct lifestyle counseling programs
- Body‑weight outcomes in participants with metabolic disease
These studies reflect a patient‑centered approach to managing metabolic disease at Poliklinika Slavonija Osijek.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Novo Nordisk A/S3active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S5trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Poliklinika SLAVONIJA OSIJEK za opcu kirurgiju radiologiju baromedicinu ginekologiju i porodiljstvo i internu medicinu
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Dose-Finding Study to Evaluate the Efficacy and Safety of Once-Weekly Subcutaneous NNC0662-0419 in Participants with Type 2 Diabetes | Novo Nordisk A/S | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 3 | Unknown | 2023-11-07 | 2026-05-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.